Logo image of ITOS

ITEOS THERAPEUTICS INC (ITOS) Stock Fundamental Analysis

NASDAQ:ITOS - Nasdaq - US46565G1040 - Common Stock - Currency: USD

10.11  -0.02 (-0.2%)

After market: 10.11 0 (0%)

Fundamental Rating

4

ITOS gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 551 industry peers in the Biotechnology industry. While ITOS has a great health rating, there are worries on its profitability. ITOS does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year ITOS has reported negative net income.
In the past year ITOS has reported a negative cash flow from operations.
In multiple years ITOS reported negative net income over the last 5 years.
ITOS had negative operating cash flow in 4 of the past 5 years.
ITOS Yearly Net Income VS EBIT VS OCF VS FCFITOS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 0 200M 400M

1.2 Ratios

With a decent Return On Assets value of -19.57%, ITOS is doing good in the industry, outperforming 78.22% of the companies in the same industry.
ITOS has a better Return On Equity (-22.77%) than 82.58% of its industry peers.
Industry RankSector Rank
ROA -19.57%
ROE -22.77%
ROIC N/A
ROA(3y)-7.87%
ROA(5y)-2.39%
ROE(3y)-9.26%
ROE(5y)-0.48%
ROIC(3y)N/A
ROIC(5y)N/A
ITOS Yearly ROA, ROE, ROICITOS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 0 -50 -100 -150

1.3 Margins

ITOS does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ITOS Yearly Profit, Operating, Gross MarginsITOS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 0 -200 -400 -600 -800 -1K

More info and screens

8

2. Health

2.1 Basic Checks

ITOS does not have a ROIC to compare to the WACC, probably because it is not profitable.
ITOS has more shares outstanding than it did 1 year ago.
ITOS has more shares outstanding than it did 5 years ago.
There is no outstanding debt for ITOS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
ITOS Yearly Shares OutstandingITOS Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M
ITOS Yearly Total Debt VS Total AssetsITOS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

2.2 Solvency

An Altman-Z score of 2.86 indicates that ITOS is not a great score, but indicates only limited risk for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 2.86, ITOS is in the better half of the industry, outperforming 71.69% of the companies in the same industry.
ITOS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 2.86
ROIC/WACCN/A
WACC11.13%
ITOS Yearly LT Debt VS Equity VS FCFITOS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 200M 400M 600M

2.3 Liquidity

ITOS has a Current Ratio of 12.62. This indicates that ITOS is financially healthy and has no problem in meeting its short term obligations.
ITOS's Current ratio of 12.62 is amongst the best of the industry. ITOS outperforms 84.39% of its industry peers.
ITOS has a Quick Ratio of 12.62. This indicates that ITOS is financially healthy and has no problem in meeting its short term obligations.
ITOS has a better Quick ratio (12.62) than 84.39% of its industry peers.
Industry RankSector Rank
Current Ratio 12.62
Quick Ratio 12.62
ITOS Yearly Current Assets VS Current LiabilitesITOS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

More info and screens

3

3. Growth

3.1 Past

ITOS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 19.05%, which is quite good.
The Revenue has grown by 177.89% in the past year. This is a very strong growth!
The Revenue for ITOS have been decreasing by -53.35% on average. This is quite bad
EPS 1Y (TTM)19.05%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%25.23%
Revenue 1Y (TTM)177.89%
Revenue growth 3Y-53.35%
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 3.35% on average over the next years.
Based on estimates for the next years, ITOS will show a very negative growth in Revenue. The Revenue will decrease by -14.87% on average per year.
EPS Next Y2.52%
EPS Next 2Y17.98%
EPS Next 3Y22.83%
EPS Next 5Y3.35%
Revenue Next Year-100%
Revenue Next 2Y-61.63%
Revenue Next 3Y-25.99%
Revenue Next 5Y-14.87%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
ITOS Yearly Revenue VS EstimatesITOS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2022 2023 2024 2026 2030 2031 2032 100M 200M 300M
ITOS Yearly EPS VS EstimatesITOS Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2 4

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ITOS. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ITOS. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ITOS Price Earnings VS Forward Price EarningsITOS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ITOS Per share dataITOS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10

4.3 Compensation for Growth

ITOS's earnings are expected to grow with 22.83% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y17.98%
EPS Next 3Y22.83%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ITOS!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ITEOS THERAPEUTICS INC

NASDAQ:ITOS (8/8/2025, 8:00:02 PM)

After market: 10.11 0 (0%)

10.11

-0.02 (-0.2%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-07 2025-08-07/bmo
Earnings (Next)11-10 2025-11-10/bmo
Inst Owners104.81%
Inst Owner Change-0.56%
Ins Owners1.18%
Ins Owner Change5.21%
Market Cap446.56M
Analysts50
Price Target10.85 (7.32%)
Short Float %8.13%
Short Ratio1.87
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-5.35%
Min EPS beat(2)-15.79%
Max EPS beat(2)5.09%
EPS beat(4)3
Avg EPS beat(4)22.2%
Min EPS beat(4)-15.79%
Max EPS beat(4)82.99%
EPS beat(8)7
Avg EPS beat(8)25.01%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-9.47%
PT rev (3m)-57.45%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)20.94%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)N/A
Revenue NY rev (3m)-100%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 12.76
P/FCF N/A
P/OCF N/A
P/B 0.76
P/tB 0.76
EV/EBITDA N/A
EPS(TTM)-3.06
EYN/A
EPS(NY)-2.02
Fwd EYN/A
FCF(TTM)-2.26
FCFYN/A
OCF(TTM)-2.22
OCFYN/A
SpS0.79
BVpS13.36
TBVpS13.36
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -19.57%
ROE -22.77%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-7.87%
ROA(5y)-2.39%
ROE(3y)-9.26%
ROE(5y)-0.48%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.05
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 133.93%
Cap/Sales 4.74%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 12.62
Quick Ratio 12.62
Altman-Z 2.86
F-Score4
WACC11.13%
ROIC/WACCN/A
Cap/Depr(3y)204.25%
Cap/Depr(5y)178.55%
Cap/Sales(3y)9.83%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)19.05%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%25.23%
EPS Next Y2.52%
EPS Next 2Y17.98%
EPS Next 3Y22.83%
EPS Next 5Y3.35%
Revenue 1Y (TTM)177.89%
Revenue growth 3Y-53.35%
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year-100%
Revenue Next 2Y-61.63%
Revenue Next 3Y-25.99%
Revenue Next 5Y-14.87%
EBIT growth 1Y-5.69%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year25.22%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y6.54%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y5.37%
OCF growth 3YN/A
OCF growth 5YN/A